The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature

Scarfì, Federica; Patrizi, Annalisa; Veronesi, Giulia; Lambertini, Martina; Tartari, Federico; Mussi, Martina; Melotti, Barbara; Dika, Emi

doi:10.1111/dth.14165

Cited by 26 publications

(23 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since some symptoms of COVD-19 can mimic the flu-like syndrome of imiquimod [31], app-based decision-making is an important part of the treatment. In general, imiquimod mostly induces mild to moderate symptoms, but severe flu-like syndromes can occur [32]. Previous studies using the same treatment regimen (imiquimod, 5-fluorouracil, and tretinoin) on individual keratinocyte carcinomas also demonstrated that treatments induce mostly mild to moderate symptoms [33,34].…”

Section: Discussionmentioning

confidence: 99%

Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin

Nahm

Gwillim

Badiavas

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

The recent coronavirus disease 2019 (COVID-19) pandemic has created a quandary for the physician in terms of evaluating and treating cutaneous skin cancers, particularly melanomas. At the onset of the pandemic, many planned medical and surgical visits for skin cancers were postponed. Physicians and patients have had to balance the risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with that of worsening morbidity and mortality due to delays in skin cancer treatments. We present a male patient who had two melanoma-in-situs (MISs) that were treated during the COVID-19 pandemic with a combination of topical imiquimod 5% cream, 5-fluorouracil 2% solution, and tretinoin 0.1% cream. The successful treatments occurred without in-person visits and with the aid of telemedicine. Although surgery is the standard for the treatment of melanoma in situ, this case demonstrates an effective viable treatment modality for MIS during a pandemic situation.

show abstract

Section: Discussionmentioning

confidence: 99%

Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin

Nahm

Gwillim

Badiavas

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…Another combination that could play a role in the treatment of VCs (in particular VPD) is represented by imiquimod plus ICIs. In selected patients, imiquimod combined with other treatments has been shown to be effective in the local control of skin metastases from melanoma [168] and breast cancer [169,170]. Finally, some reports show a benefit of imiquimod-plus-ICIs combinations in advanced melanomas [171,172].…”

Section: Discussionmentioning

confidence: 99%

Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review

Borella

Preti

Bertero

et al. 2020

IJMS

View full text Add to dashboard Cite

Vulvar cancer (VC) is a rare neoplasm, usually arising in postmenopausal women, although human papilloma virus (HPV)-associated VC usually develop in younger women. Incidences of VCs are rising in many countries. Surgery is the cornerstone of early-stage VC management, whereas therapies for advanced VC are multimodal and not standardized, combining chemotherapy and radiotherapy to avoid exenterative surgery. Randomized controlled trials (RCTs) are scarce due to the rarity of the disease and prognosis has not improved. Hence, new therapies are needed to improve the outcomes of these patients. In recent years, improved knowledge regarding the crosstalk between neoplastic and tumor cells has allowed researchers to develop a novel therapeutic approach exploiting these molecular interactions. Both the innate and adaptive immune systems play a key role in anti-tumor immunesurveillance. Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in multiple tumor types, improving survival rates and disease outcomes. In some gynecologic cancers (e.g., cervical cancer), many studies are showing promising results and a growing interest is emerging about the potential use of ICIs in VC. The aim of this manuscript is to summarize the latest developments in the field of VC immunoncology, to present the role of state-of-the-art ICIs in VC management and to discuss new potential immunotherapeutic approaches.

show abstract

“…Imiquimod has been successfully applied in the treatment of melanoma as presented in a large number of recent case reports [ 288 , 289 , 290 , 291 ]. Additionally, the topical use of imiquimod for melanoma cutaneous metastases has been well documented, concluding that it is useful in selected cases and is generally well tolerated [ 292 ].…”

Section: Neuropeptides and Melanomamentioning

confidence: 99%

Neuroendocrine Factors in Melanoma Pathogenesis

Scheau

Drăghici

Ilie

et al. 2021

Cancers

View full text Add to dashboard Cite

Melanoma is one of the most aggressive skin cancers with a sharp rise in incidence in the last decades, especially in young people. Recognized as a significant public health issue, melanoma is studied with increasing interest as new discoveries in molecular signaling and receptor modulation unlock innovative treatment options. Stress exposure is recognized as an important component in the immune-inflammatory interplay that can alter the progression of melanoma by regulating the release of neuroendocrine factors. Various neurotransmitters, such as catecholamines, glutamate, serotonin, or cannabinoids have also been assessed in experimental studies for their involvement in the biology of melanoma. Alpha-MSH and other neurohormones, as well as neuropeptides including substance P, CGRP, enkephalin, beta-endorphin, and even cellular and molecular agents (mast cells and nitric oxide, respectively), have all been implicated as potential factors in the development, growth, invasion, and dissemination of melanoma in a variety of in vitro and in vivo studies. In this review, we provide an overview of current evidence regarding the intricate effects of neuroendocrine factors in melanoma, including data reported in recent clinical trials, exploring the mechanisms involved, signaling pathways, and the recorded range of effects.

show abstract

The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature

Cited by 26 publications

References 67 publications

Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin

Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin

Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review

Neuroendocrine Factors in Melanoma Pathogenesis

Contact Info

Product

Resources

About